Chong Kun Dang announced on May 27 that it recently announced the clinical results of the treatment of dyslipidemia drug "Lipilou" at the annual academic conference of the American Heart Association (AHA), which was held online.
The "PEARL Study" was conducted to check the effectiveness and economic feasibility of 10 milligrams of Lipilou and 20 milligrams of Lipilou in high-risk hypercholesterolemia Koreans.
The research team led by Professor Kim Jin-won of the Department of Circular Internal Medicine at Korea Medical University divided 237 patients with high-risk and ultra-high-risk groups based on guidelines for dyslipidemia in Korea into two groups and administered 10 mg and 20 mg of Lipilou for 12 weeks, respectively, and then conducted an economic evaluation of low-density lipoprotein cholesterol (LDL-C) levels that are bad for the body.
According to the study, the Lipilou 10mg administration group's low-density lipoprotein cholesterol (LDL-C) level dropped 33.5% after 12 weeks, and the 20mg administration group saw a 42.4% drop in cholesterol level, both sides with lower levels of cholesterol.
While statin-type dyslipidemia treatments have an average LDL-C drop of 6% as drug doses increase, the Lipilou 20 mg has shown an additional 9% drop compared to 10 mg, making it more effective.
In the economic assessment, the second evaluation index, the average cost-effectiveness ratio (ACER) of 10 mg was 2,604 won for a 1% decrease in cholesterol level, while 20 mg was 2,074 won, which is 20 percent cheaper.
"This study is significant in that it conducted both a dose-specific drug efficacy and economic assessment of patients with high-risk groups in Korea at the same time," a Chong Kun Dang official said. "The results of this study suggest another standard for medication for the treatment of dyslipidemia patients."
It announced new clinical results of Lipilou for women after menopause at the World Diabetes Federation in 2018. It also announced the results of large-scale safety surveys at a number of international academic conferences, proving its effectiveness and safety.
